Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Blood Component Transfusion”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 181 records · Page 10Linked to original sources
PubMed1994

[HLA and transfusion].

Using published data, the role of the HLA system for transfusion of cellular blood components is described. Transfusion-associated immunomodulation and the causative role of HLA in other side effects of transfusion therapy are discussed, using review articles and original papers from the German and English literature as sources. The HLA system has important implications for transfusion therapy. Sensibilization of recipients with consecutive formation of HLA antibodies impairs the support of thrombocytopenic patients and may cause febrile transfusion reactions. HLA antibody formation in donors may result in transfusion-induced acute lung injury. The transfusion of viable lymphocytes may cause graft-versus-host disease in immunocompromised recipients or after directed donations from relatives, in rare cases even without these conditions. The clinical implications of transfusion-associated immunomodulation are judged differently.

Blood Component Transfusion↗
PubMed1993

Transfusion therapy in the emergency department.

This article reviews the basics of blood and blood component therapy, focusing on pretransfusion compatibility testing and the complications of blood transfusion (both infectious and noninfectious). Issues surrounding the massive transfusion of blood and alternatives to traditional chemotherapy also are discussed.

Blood Banks↗
PubMed1991

The role of the blood bank in transplantation.

Blood transfusion supportive care is essential to successful organ, tissue, and bone marrow transplantation, thus making the blood bank an integral part of these programs. The impact of clinical transplantation on the blood bank can be considered in the following categories: (1) use of blood and blood components for transfusion support; (2) special blood component needs; (3) red blood cell serologic needs; (4) collection, processing, and preservation of bone marrow and peripheral blood stem cells; (5) hemotherapy for bone marrow donors, (6) recruitment of bone marrow donors; and (7) the special procedures that must be available for managing patients undergoing transplantation therapy.

Blood↗
PubMed1995

Management of the Jehovah's Witness Oncology Patient: Perspective of the Transfusion Service.

Due to refusal of blood component transfusions, Jehovah's Witness patients with cancer present a challenge to oncologists who must find appropriate and acceptable treatments. In order to assess the morbidity and mortality that these patients suffer, a retrospective review was conducted of all 58 Jehovah's Witness patients treated at our center from October 1986 through February 1994. This study showed that (1) younger Jehovah's Witness patients or their parents were more likely to accept blood transfusion than older Jehovah's Witness patients, (2) considerable risk of acute morbidity and mortality occurred in patients who refused blood when blood transfusions were indicated, and (3) long-term prognosis may be worsened for some Jehovah's Witness patients due to limited treatment provided in those with anemia or with anticipated anemia.

Journal Article↗
PubMed2005

ABO incompatible transfusions--experience from the UK Serious Hazards of Transfusion (SHOT) scheme Transfusions ABO incompatible.

The Serious Hazards of Transfusion (SHOT) scheme has now accumulated 8 years' data. The most frequently occurring adverse event, accounting for 1832/2628 (70%) of incidents reported, is 'incorrect blood component transfused' (IBCT) in which the patient receives a blood component that did not meet the correct specification or that was intended for another patient. Errors can occur at all stages of the transfusion chain and, in about half of cases, multiple system failures can be identified. Analysis of 130 ABO incompatible transfusions reported between 1999 and 2003 identified 221 separate errors, 68% of which took place in clinical areas and 29% in hospital laboratories. The commonest single error is failure to check at the bedside that the right blood is being given to the right patient. Certain patients, e.g. neonates, those transfused at night and in critical care situations, appear to be particularly vulnerable. It is encouraging that, against a background of ever increasing numbers year-on-year of reports of IBCT, the incidence of ABO incompatible transfusions already shows a downward trend, suggesting the emergence of a safety culture.

ABO Blood-Group System↗
PubMed2004

Transfusion of RhD-incompatible blood components in RhD-negative blood marrow transplant recipients.

BACKGROUND: Transfusion-dependent bone marrow transplant recipients are routinely transfused with ABO group and RhD-compatible blood components. However, because of the scarcity of RhD-negative blood components, particularly platelets, a policy was developed to transfuse RhD-positive blood components to RhD-negative patients during periods of shortage. METHODS: We reviewed the records of 78 RhD-negative patients with hematologic malignancies who received RhD-negative bone marrow and/or peripheral blood stem cells, from June 1995 to August 2000. The patients transfused with RhD-incompatible blood components were screened periodically for evidence of the development of red blood cell (RBC) alloimmunization. RESULTS: Three of 78 patients (4%) developed anti-D antibodies after receiving RhD-incompatible platelet transfusions. One of the patients developed evidence of anti-RhD antibodies after receiving 42 units of RhD-positive random donor platelets; the second patient developed such evidence after receiving 6 apheresis platelets and 2 infusions of intravenous immunoglobulin G (positive for anti-RhD). The third patient received 206 RhD-positive random donor platelets and 5 apheresis units. All patients were discharged from the hospital. The overall immunization rate was 4%. Six patients received Rh-incompatible packed RBCs and showed no evidence of neither anti-RhD nor any other anti-RBC antibodies. All 78 patients had received RhD-incompatible platelets throughout their engraftment period. CONCLUSION: Transfusion of RhD-positive blood components to Rh-negative patients with hematologic cancers, who have received RhD-negative bone marrow and/or peripheral blood stem cells, are at low risk of developing RhD antibodies. These findings allow for a flexible strategy of blood component therapy support for this special patient population during periods of shortage.

Adult↗
PubMed2002

Probability of receiving testing in a national lookback program: the English HCV experience.

BACKGROUND: The HCV lookback program was designed to trace and offer testing to recipients who received transfusion of blood components from donors subsequently found to be anti-HCV positive. Only approximately 20 percent of transfusable components entering lookback did result in a recipient obtaining testing through this program. STUDY DESIGN AND METHODS: Data from English blood centers were collated to describe the outcomes of the HCV lookback program. The data were used to assess factors affecting the likelihood that recipients of lookback components received testing by the program. RESULTS: In total, 4424 recipients of 6687 blood components that had been issued for transfusion were identified. The lookback resulted in a tested recipient for 1067 components. Factors positively associated with receiving testing in identified recipients were younger age at transfusion, more recent year of transfusion, certain component types, and transfusion under the care of certain medical specialties; these effects were largely explained by the association of these factors with survival after transfusion. CONCLUSIONS: Not accepting testing through this program was largely due to death before the lookback and partly due to inability to access information from records and to decisions that testing was not in recipients' best interests. The probability of obtaining testing through this lookback was associated with several factors that could be used to focus the efforts of similar lookbacks in the future.

Adult↗